JP2016106117A5 - - Google Patents

Download PDF

Info

Publication number
JP2016106117A5
JP2016106117A5 JP2016032672A JP2016032672A JP2016106117A5 JP 2016106117 A5 JP2016106117 A5 JP 2016106117A5 JP 2016032672 A JP2016032672 A JP 2016032672A JP 2016032672 A JP2016032672 A JP 2016032672A JP 2016106117 A5 JP2016106117 A5 JP 2016106117A5
Authority
JP
Japan
Prior art keywords
immunogenic composition
chlamydia
antigen
subject
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016032672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016106117A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016106117A publication Critical patent/JP2016106117A/ja
Publication of JP2016106117A5 publication Critical patent/JP2016106117A5/ja
Pending legal-status Critical Current

Links

JP2016032672A 2010-10-20 2016-02-24 クラミジア抗原及びその使用 Pending JP2016106117A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40516210P 2010-10-20 2010-10-20
US61/405,162 2010-10-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013535100A Division JP2013545448A (ja) 2010-10-20 2011-10-20 クラミジア抗原及びその使用

Publications (2)

Publication Number Publication Date
JP2016106117A JP2016106117A (ja) 2016-06-16
JP2016106117A5 true JP2016106117A5 (enExample) 2017-01-05

Family

ID=45975625

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013535100A Pending JP2013545448A (ja) 2010-10-20 2011-10-20 クラミジア抗原及びその使用
JP2016032672A Pending JP2016106117A (ja) 2010-10-20 2016-02-24 クラミジア抗原及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013535100A Pending JP2013545448A (ja) 2010-10-20 2011-10-20 クラミジア抗原及びその使用

Country Status (6)

Country Link
US (2) US20120135025A1 (enExample)
EP (1) EP2629793A4 (enExample)
JP (2) JP2013545448A (enExample)
AU (2) AU2011316924A1 (enExample)
CA (1) CA2849391A1 (enExample)
WO (1) WO2012054755A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2585961C9 (ru) 2009-05-22 2016-12-27 Дженосеа Биосайенсиз Инк. Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
JP2013525271A (ja) 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
JP6055776B2 (ja) 2010-11-24 2016-12-27 ジェノセア バイオサイエンシーズ, インコーポレイテッド 単純ヘルペスウイルス2型に対するワクチン:免疫応答を誘発する組成物及び方法
JP6199878B2 (ja) * 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ, インコーポレイテッド 単純ヘルペスウイルス2型に対する核酸ワクチン:免疫応答を誘発する組成物及び方法
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
EP3519427A4 (en) 2016-09-28 2020-03-11 Genocea Biosciences Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES
JP6741919B2 (ja) 2016-10-14 2020-08-19 パナソニックIpマネジメント株式会社 プロジェクションシステム、プロジェクション方法、飛行体システム及び飛行体
CN112969474A (zh) 2018-09-12 2021-06-15 艾芬尼维克斯公司 多价肺炎球菌疫苗
MX2023008986A (es) * 2021-01-29 2023-08-15 Inst Nat Sante Rech Med Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna.
MX2024002779A (es) 2021-09-09 2024-06-11 Affinivax Inc Vacunas neumocócicas multivalentes.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041490B1 (en) * 1997-11-28 2006-05-09 Serono Genetics Institute, S.A. Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same
EP1133572A4 (en) * 1998-11-12 2005-06-15 Univ California GENOME SEQUENCE OF CHLAMYDIA PNEUMONIAE
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
ES2386386T3 (es) * 2001-12-12 2012-08-20 Novartis Vaccines And Diagnostics S.R.L. Inmunización contra Chlamydia trachomatis
EP1597275B1 (en) * 2003-02-24 2010-08-18 Institut Pasteur Use of the Chlamydia pneumoniae CPn0104 polypeptide or antibodies thereto to diagnose Chlamydia infections
WO2005002619A2 (en) * 2003-06-26 2005-01-13 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
JP5024830B2 (ja) * 2004-10-25 2012-09-12 ステーテンズ セーラム インスティテュート クラミジア・トラコマチス(Chlamydiatrachomatis)抗原のワクチンおよび診断への使用
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
WO2007110700A2 (en) * 2005-12-22 2007-10-04 Novartis Vaccines And Diagnostics, Srl. Chlamydial antigens
US9068007B2 (en) * 2008-10-09 2015-06-30 Board Of Regents, The University Of Texas System Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease
CA2781805A1 (en) * 2008-12-17 2010-07-08 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
WO2010100632A2 (en) * 2009-03-06 2010-09-10 Novartis Ag Chlamydia antigens

Similar Documents

Publication Publication Date Title
JP2016040284A5 (enExample)
JP2013545448A5 (enExample)
JP2011250797A5 (enExample)
JP2015214545A5 (enExample)
PH12021553146A1 (en) Fusion proteins for tuberculosis vaccines
JP2013507907A5 (enExample)
HRP20220924T1 (hr) Imunoterapija zasnovana na pd-l1
JP2014534202A5 (enExample)
JP2014240404A5 (enExample)
TW200722101A (en) Novel composition
CN106659777A8 (zh) 免疫原性组合产品
NZ759686A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP2016539946A5 (enExample)
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
JP2012512257A5 (enExample)
JP2007538044A5 (enExample)
WO2015095249A8 (en) Single chain il-12 nucleic acids, polypeptids, and uses thereof
JP2013518052A5 (enExample)
WO2013082535A3 (en) Controlled-release peptide compositions and uses thereof
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
BRPI1007721B1 (pt) composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66
JP2016514713A5 (enExample)
JP2015529677A5 (enExample)
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
WO2019072871A3 (en) Microbiota sequence variants of tumor-related antigenic epitopes